Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles.

We sought to develop a nanoparticle vehicle that could efficiently deliver small molecule drugs to target lymphocyte populations. The synthesized amphiphilic organic ligand-protected gold nanoparticles (amph-NPs) were capable of sequestering large payloads of small molecule drugs within hydrophobic pockets of their ligand shells. These particles exhibit membrane-penetrating activity in mammalian cells, and thus enhanced uptake of a small molecule TGF-β inhibitor in T cells in cell culture. By conjugating amph-NPs with targeting antibodies or camelid-derived nanobodies, the particles' cell-penetrating properties could be temporarily suppressed, allowing targeted uptake in specific lymphocyte subpopulations. Degradation of the protein targeting moieties following particle endocytosis allowed the NPs to recover their cell-penetrating activity in situ to enter the cytoplasm of T cells. In vivo, targeted amph-NPs showed 40-fold enhanced uptake in CD8+ T cells relative to untargeted particles, and delivery of TGF-β inhibitor-loaded particles to T cells enhanced their cytokine polyfunctionality in a cancer vaccine model. Thus, this system provides a facile approach to concentrate small molecule compounds in target lymphocyte populations of interest for immunotherapy in cancer and other diseases.

[1]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[2]  Rebecca L. Holden,et al.  Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability , 2018, Cancer Immunology Research.

[3]  R. Weinberg,et al.  Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells , 2017, The Journal of experimental medicine.

[4]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[5]  Li Tang,et al.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. , 2017, ACS nano.

[6]  Prabhani U. Atukorale,et al.  High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry , 2017, Nature Communications.

[7]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[8]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[9]  Francesco Stellacci,et al.  Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes. , 2015, Nanoscale.

[10]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[11]  Jérôme Cros,et al.  Targeting the TGFβ pathway for cancer therapy. , 2015, Pharmacology & therapeutics.

[12]  J. Tchou,et al.  Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. , 2014, Immunity.

[13]  F. Stellacci,et al.  Lipid tail protrusions mediate the insertion of nanoparticles into model cell membranes , 2014, Nature Communications.

[14]  Yuhua Wang,et al.  Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment , 2014, ACS nano.

[15]  Prabhani U. Atukorale,et al.  Effect of particle diameter and surface composition on the spontaneous fusion of monolayer-protected gold nanoparticles with lipid bilayers. , 2013, Nano letters.

[16]  Darrell J Irvine,et al.  In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Richard A Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[18]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[19]  R. Jain,et al.  TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma , 2012, Proceedings of the National Academy of Sciences.

[20]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[21]  T. Hahn,et al.  The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis , 2012, Cancer Immunology, Immunotherapy.

[22]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[23]  J. Allison,et al.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. , 2011, Immunity.

[24]  Li Yang,et al.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. , 2010, Trends in immunology.

[25]  J. Berzofsky,et al.  Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells , 2010, International journal of cancer.

[26]  K. Garber.  Companies waver in efforts to target transforming growth factor beta in cancer. , 2009, Journal of the National Cancer Institute.

[27]  V. Rotello,et al.  Entrapment of hydrophobic drugs in nanoparticle monolayers with efficient release into cancer cells. , 2009, Journal of the American Chemical Society.

[28]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[29]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[30]  Francesco Stellacci,et al.  Water-soluble amphiphilic gold nanoparticles with structured ligand shells. , 2008, Chemical communications.

[31]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[32]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[33]  R. Flavell,et al.  Transforming growth factor (TGF-) and autoimmunity , 2005 .

[34]  S. Rosenberg,et al.  TGF-β1 Attenuates the Acquisition and Expression of Effector Function by Tumor Antigen-Specific Human Memory CD8 T Cells , 2005, The Journal of Immunology.

[35]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[36]  J. Frère,et al.  β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae , 2001, Antimicrobial Agents and Chemotherapy.

[37]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[38]  A. Plückthun,et al.  Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. , 1988, Science.

[39]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.